(Q28476125)

English

Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis

scientific article

In more languages

Statements

scholarly article

0 references

4 references

23 March 2019

22 June 2019

20 August 2019

21 October 2020

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis (English)

0 references

0 references

0 references

0 references

pulmonary tuberculosis

4 references

23 March 2019

22 June 2019

20 August 2019

21 October 2020

physiological phenomenon

1 reference

20 August 2019

bacterial drug resistance

1 reference

21 October 2020

systematic review

1 reference

based on heuristic

inferred from title

0 references

1

0 references

Christian Lienhardt

8

object named as

Christian Lienhardt

0 references

author name string

Andrea Benedetti

2

0 references

Anita Paydar

3

0 references

Sarah Royce

4

0 references

Pai Madhukar

5

0 references

William Burman

6

0 references

Andrew Vernon

7

0 references

language of work or name

0 references

publication date

September 2009

0 references

1 September 2009

4 references

23 March 2019

22 June 2019

20 August 2019

21 October 2020

4 references

23 March 2019

22 June 2019

20 August 2019

21 October 2020

6

0 references

9

0 references

e1000150

0 references

copyright license

Creative Commons CC0 License

4 references

Europe PubMed Central

23 March 2019

Europe PubMed Central

22 June 2019

Europe PubMed Central

20 August 2019

Europe PubMed Central

21 October 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

19 March 2017

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

19 March 2017

Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

19 March 2017

A comparative study of daily followed by twice or once weekly regimens of ethambutol and rifampicin in retreatment of patients with pulmonary tuberculosis. The results at 1 year. A cooperative tuberculosis chemotherapy study in Poland

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

19 March 2017

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

7 April 2017

A bibliometric analysis of tuberculosis research indexed in PubMed, 1997-2006.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

29 September 2017

Randomized trials to optimize treatment of multidrug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

29 September 2017

Isoniazid preventive therapy and risk for resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

29 September 2017

Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

29 September 2017

Controlling the risk of spurious findings from meta-regression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

29 September 2017

Investigating causes of heterogeneity in systematic reviews

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

29 September 2017

HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

29 September 2017

Drug-resistant tuberculosis in South African gold miners: incidence and associated factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

29 September 2017

A trial of intermittent rifampicin and ethambutol in retreatment regimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

29 September 2017

Ambulatory intermittent rifampicin and ethambutol in the retreatment of pulmonary tuberculosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

2 June 2018

[Controlled study comparing 3 daily chemotherapy regimens for six months in pulmonary tuberculosis in routine practice in Algiers. Results at 30 months]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

2 June 2018

Clinical trial of two short-course (6-month) regimens and a standard regimen (12-month) chemotherapy in retreatment of pulmonary tuberculosis in Pakistan. Results 18 months after completion of treatment (Lahore Tuberculosis Study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

2 June 2018

Comparison of a daily and three intermittent retreatment regimens for pulmonary tuberculosis administered under programme conditions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

2 June 2018

Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

2 June 2018

Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

2 June 2018

[A therapeutic trial of a combination of 3 essential drugs in a short course of chemotherapy in tuberculosis. Results 6 months after the end of treatment]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

2 June 2018

The Mutual Assistance Programme of the IUATLD. Development, contribution and significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

2 June 2018

Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000150

21 January 2018

The binomial distribution of meta-analysis was preferred to model within-study variability.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000150

21 January 2018

Explaining heterogeneity in meta-analysis: a comparison of methods.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000150

21 January 2018

Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000150

21 January 2018

Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000150

21 January 2018

A Controlled Trial of 3-Month, 4-Month, and 6-Month Regimens of Chemotherapy for Sputum-smear-negative Pulmonary Tuberculosis: Results at 5 Years

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000150

21 January 2018

Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

27 November 2018

Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

27 November 2018

Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

27 November 2018

Revised international definitions in tuberculosis control.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

27 November 2018

Low failure rate in standardised retreatment of tuberculosis in Nicaragua: patient category, drug resistance and survival of 'chronic' patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

27 November 2018

Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

27 November 2018

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis: first report: Third East African/British Medical Research Councils study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2736403

27 November 2018

Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retreatment of chronic pulmonary tuberculosis with regimens including high and low doses of rifampicin in the intermittent phase recent and late results - a controlled comparison study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment outcome of relapse and defaulter pulmonary tuberculosis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculo

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of treatment outcome in re-treatment versus new smear positive cases of tuberculosis under RNTCP

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

From Threat to Reality

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 month

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Cambridge Declaration: towards clinical trials for drug-resistant tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens of 28 and 36 weeks duration in Algeria. Algerian Working Group/British Medical Research Council Cooperative Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled clinical comparison of 6 and 8 months of antituberculosis chemotherapy in the treatment of patients with silicotuberculosis in Hong Kong. Hong Kong Chest Service/tuberculosis Research Centre, Madras/British Medical Research Council

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis. A Kenyan/Zambian/British Medical Research Council Collaborative Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled clinical trial of two 6-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Tanzania/British Medical Research Council Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: The results up to 24 months

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled clinical trial of daily and intermittent regimens of rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis in Hong Kong. A Hong Kong Tuberculosis Treatment Services/Brompton Hospital/British Medical Resea

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifomycin in treatment of chronic tuberculosis with bacilli resistant to standard medications

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifampicin, ethambutol, ethionamide and hydronsan in advanced pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singapore

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Second report. Third East African/British Medical Research Council Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Algerian working group/British Medical Research Council cooperative study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled trial of a 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. East African/British Medical Research Councils Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Short-course (6-month) cooperative tuberculosis study in Poland: results 30 months after completion of treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Clinical trial of a combination of three drugs in fixed proportions in the treatment of tuberculosis. Groupe de Travail sur la Chimiothérapie de la Tuberculose]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. East African and British Medical Research Councils

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative study of daily followed by twice- or once-weekly regimens of ethambutol and rifampicin in the retreatment of patients with pulmonary tuberculosis: second report

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre

1 reference

https://pubmed.ncbi.nlm.nih.gov/20101802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28476125&oldid=2139620105"